X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-04-15 | LNTH | Lantheus Holdings, Inc. | Sabens Andrea | Chief Accounting Officer | S - Sale | $61.24 | -341 | 63,239 | -1% | -$20,883 | ||||||
2024-04-17 | NEOG | Neogen Corp | Jones Douglas Edward | COO | P - Purchase | $12.36 | +10,000 | 46,131 | +28% | +$123,590 | ||||||
| D | 2024-04-11 | OCX | Oncocyte Corp | Broadwood Partners, L.P. | 10% | P - Purchase | $2.92 | +2,420,000 | 9,858,289 | +33% | +$7,057,688 | |||||
2024-04-11 | OCX | Oncocyte Corp | Riggs Josh | CEO, Pres | P - Purchase | $2.95 | +3,390 | 3,505 | >999% | +$10,001 | ||||||
2024-04-11 | OCX | Oncocyte Corp | Arno Andrew | Dir | P - Purchase | $2.95 | +33,898 | 84,662 | +67% | +$99,999 | ||||||
2024-04-11 | NEOG | Neogen Corp | Borel James C | Dir | P - Purchase | $13.06 | +7,500 | 21,392 | +54% | +$97,986 | ||||||
2024-04-10 | NEOG | Neogen Corp | Naemura David H. | CFO | P - Purchase | $12.51 | +12,500 | 30,040 | +71% | +$156,321 | ||||||
2024-04-10 | NEOG | Neogen Corp | Adent John Edward | CEO | P - Purchase | $12.36 | +23,000 | 152,389 | +18% | +$284,190 | ||||||
2024-03-15 | LNTH | Lantheus Holdings, Inc. | Marshall Robert J. Jr. | CFO, Treasurer | S - Sale | $60.00 | -20,000 | 113,749 | -15% | -$1,200,000 | ||||||
2024-03-13 | LNTH | Lantheus Holdings, Inc. | Sabens Andrea | Chief Accounting Officer | S - Sale | $60.48 | -341 | 63,204 | -1% | -$20,624 | ||||||
2024-03-07 | LNTH | Lantheus Holdings, Inc. | Blanchfield Paul | Pres | S - Sale | $61.96 | -18,023 | 102,857 | -15% | -$1,116,705 | ||||||
2024-03-06 | CATX | Perspective Therapeutics, Inc. | Lantheus Alpha Therapy, LLC | 10% | P - Purchase | $0.95 | +60,431,039 | 116,773,394 | +107% | +$57,409,487 | ||||||
| D | 2024-03-06 | IDXX | Idexx Laboratories Inc /de | Polewaczyk James F | EVP | S - Sale+OE | $558.44 | -8,104 | 10,711 | -43% | -$4,525,596 | |||||
| D | 2024-03-05 | IDXX | Idexx Laboratories Inc /de | Vandebroek Sophie V. | Dir | S - Sale+OE | $562.98 | -1,404 | 9,389 | -13% | -$790,427 | |||||
| DM | 2024-03-05 | LNTH | Lantheus Holdings, Inc. | Leno Sam R | Dir | S - Sale+OE | $64.06 | -4,090 | 57,937 | -7% | -$262,005 | |||||
| D | 2024-03-04 | LNTH | Lantheus Holdings, Inc. | Leno Sam R | Dir | S - Sale+OE | $65.42 | -22,389 | 57,937 | -28% | -$1,464,749 | |||||
| D | 2024-03-04 | ACHV | Achieve Life Sciences, Inc. | Stewart Richard Alistair | Exec COB | P - Purchase | $4.59 | +10,000 | 38,501 | +35% | +$45,850 | |||||
| D | 2024-03-04 | ACHV | Achieve Life Sciences, Inc. | Bencich John | CEO | P - Purchase | $4.59 | +10,000 | 76,724 | +15% | +$45,850 | |||||
2024-03-04 | LNTH | Lantheus Holdings, Inc. | Heino Mary Anne | Dir | S - Sale | $65.31 | -93,863 | 630,623 | -13% | -$6,129,889 | ||||||
| D | 2024-03-04 | NTLA | Intellia Therapeutics, Inc. | Basta James | EVP, GC | S - Sale+OE | $32.99 | -2,297 | 81,571 | -3% | -$75,778 | |||||
| D | 2024-03-04 | NTLA | Intellia Therapeutics, Inc. | Clark Eliana | EVP, Chief Technical Officer | S - Sale+OE | $32.99 | -605 | 71,470 | -1% | -$19,959 | |||||
| M | 2022-08-15 | TKNO | Alpha Teknova, Inc. | Grossman Paul David | Dir | P - Purchase | $5.37 | +9,212 | 9,212 | New | +$49,504 | |||||
2024-02-23 | QDEL | Quidelortho Corp | Busky Joseph M | CFO | P - Purchase | $46.36 | +2,150 | 6,096 | +54% | +$99,663 | ||||||
2024-02-13 | LNTH | Lantheus Holdings, Inc. | Sabens Andrea | Chief Accounting Officer | S - Sale | $55.31 | -341 | 58,403 | -1% | -$18,861 | ||||||
| D | 2024-02-08 | IDXX | Idexx Laboratories Inc /de | Fennell George | SVP, Chief Revenue Officer | S - Sale+OE | $573.87 | -8,198 | 6,712 | -55% | -$4,704,559 | |||||
| D | 2024-02-07 | IDXX | Idexx Laboratories Inc /de | McKeon Brian P | EVP, CFO, Treasurer | S - Sale+OE | $570.01 | -23,326 | 47,768 | -33% | -$13,295,975 | |||||
| D | 2024-02-07 | IDXX | Idexx Laboratories Inc /de | Mazelsky Jonathan Jay | Pres, CEO | S - Sale+OE | $572.61 | -12,000 | 79,247 | -13% | -$6,871,319 | |||||
2024-02-02 | IONS | Ionis Pharmaceuticals Inc | Hougen Elizabeth L | EVP, Finance, CFO | S - Sale | $49.54 | -2,125 | 92,905 | -2% | -$105,272 | ||||||
| D | 2024-01-26 | AWH | Aspira Women'S Health Inc. | Sandford Nicole | Pres, CEO | P - Purchase | $0.00 | +2,400 | 61,103 | +4% | +$0 | |||||
| D | 2024-01-17 | IONS | Ionis Pharmaceuticals Inc | Hougen Elizabeth L | EVP, Finance, CFO | S - Sale+OE | $50.42 | -8,683 | 90,890 | -9% | -$437,771 | |||||
2024-01-16 | LNTH | Lantheus Holdings, Inc. | Sabens Andrea | Chief Accounting Officer | S - Sale | $56.01 | -341 | 58,744 | -1% | -$19,099 | ||||||
2024-01-08 | NTLA | Intellia Therapeutics, Inc. | Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | S - Sale | $28.87 | -2,275 | 43,927 | -5% | -$65,682 | ||||||
2024-01-03 | NTLA | Intellia Therapeutics, Inc. | Leonard John M | Pres, CEO | S - Sale | $29.46 | -19,223 | 904,901 | -2% | -$566,310 | ||||||
2024-01-03 | NTLA | Intellia Therapeutics, Inc. | Lebwohl David | EVP, Chief Medical Officer | S - Sale | $29.46 | -5,843 | 54,372 | -10% | -$172,135 | ||||||
2024-01-03 | NTLA | Intellia Therapeutics, Inc. | Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | S - Sale | $29.46 | -5,532 | 46,202 | -11% | -$162,973 | ||||||
2024-01-03 | NTLA | Intellia Therapeutics, Inc. | Goddard Glenn | EVP, CFO | S - Sale | $29.46 | -5,365 | 40,585 | -12% | -$158,053 | ||||||
2024-01-03 | NTLA | Intellia Therapeutics, Inc. | Hicks Derek | EVP, Chief Business Officer | S - Sale | $29.46 | -3,877 | 36,987 | -9% | -$114,216 | ||||||
2024-01-03 | NTLA | Intellia Therapeutics, Inc. | Basta James | EVP, GC | S - Sale | $29.46 | -3,805 | 51,474 | -7% | -$112,095 | ||||||
2024-01-03 | NTLA | Intellia Therapeutics, Inc. | Clark Eliana | EVP, Chief Technical Officer | S - Sale | $29.50 | -4,608 | 40,845 | -10% | -$135,954 | ||||||
2024-01-02 | VNRX | Volitionrx Ltd | Eight Corp Ltd | 10% | S - Sale | $0.90 | -20,000 | 12,005,332 | 0% | -$18,000 | ||||||
2023-12-15 | VNRX | Volitionrx Ltd | Eight Corp Ltd | 10% | S - Sale | $0.75 | -20,000 | 12,025,332 | 0% | -$15,000 | ||||||
2023-12-15 | LNTH | Lantheus Holdings, Inc. | Marshall Robert J. Jr. | CFO, Treasurer | S - Sale | $78.24 | -10,000 | 103,170 | -9% | -$782,400 | ||||||
2023-12-18 | VNRX | Volitionrx Ltd | Butera Salvatore Thomas | CEO - Volition Veterinary | P - Purchase | $0.83 | +10,000 | 278,223 | +4% | +$8,300 | ||||||
2023-12-15 | VNRX | Volitionrx Ltd | Butera Salvatore Thomas | CEO - Volition Veterinary | P - Purchase | $0.77 | +10,000 | 268,223 | +4% | +$7,700 | ||||||
2023-12-13 | LNTH | Lantheus Holdings, Inc. | Sabens Andrea | Chief Accounting Officer | S - Sale | $75.62 | -341 | 59,085 | -1% | -$25,786 | ||||||
2023-12-13 | VNRX | Volitionrx Ltd | Rootsaert Rodney Gerard | Secretary | P - Purchase | $0.60 | +10,000 | 1,086,370 | +1% | +$6,000 | ||||||
2023-12-08 | VNRX | Volitionrx Ltd | Reynolds Cameron John | Pres, CEO | P - Purchase | $0.67 | +10,000 | 2,746,312 | 0% | +$6,700 | ||||||
2023-12-06 | AWH | Aspira Women'S Health Inc. | Merchant Minh Hoang | Secretary, GC | S - Sale | $3.37 | -980 | 26,865 | -4% | -$3,303 | ||||||
| D | 2023-12-07 | IDXX | Idexx Laboratories Inc /de | Polewaczyk James F | EVP | S - Sale+OE | $521.79 | -11,636 | 10,050 | -54% | -$6,071,500 | |||||
2023-12-06 | AWH | Aspira Women'S Health Inc. | Sandford Nicole | Pres, CEO | P - Purchase | $3.36 | +5,000 | 58,703 | +9% | +$16,800 | ||||||
| D | 2023-12-04 | IDXX | Idexx Laboratories Inc /de | Mazelsky Jonathan Jay | Pres, CEO | S - Sale+OE | $513.05 | -7,128 | 79,233 | -8% | -$3,657,049 | |||||
2023-12-01 | MYGN | Myriad Genetics Inc | Riggsbee Richard Bryan | CFO | S - Sale | $19.09 | -30,000 | 291,812 | -9% | -$572,835 | ||||||
2023-11-30 | TKNO | Alpha Teknova, Inc. | Gelhaus Ken | Chief Commercial Officer | P - Purchase | $1.73 | +3,587 | 22,924 | +19% | +$6,220 | ||||||
2023-11-27 | VNRX | Volitionrx Ltd | Innes Guy Archibald | Dir | P - Purchase | $0.77 | +20,000 | 2,601,175 | +1% | +$15,400 | ||||||
2023-11-27 | VNRX | Volitionrx Ltd | Futcher Edward | Dir | P - Purchase | $0.80 | +9,000 | 427,936 | +2% | +$7,200 | ||||||
2023-11-24 | VNRX | Volitionrx Ltd | Innes Guy Archibald | Dir | P - Purchase | $0.76 | +10,000 | 2,581,175 | 0% | +$7,600 | ||||||
2023-11-22 | VNRX | Volitionrx Ltd | Innes Guy Archibald | Dir | P - Purchase | $0.71 | +20,000 | 2,571,175 | +1% | +$14,200 | ||||||
2023-11-16 | LNTH | Lantheus Holdings, Inc. | Blanchfield Paul | Pres | S - Sale | $67.96 | -1,500 | 88,651 | -2% | -$101,940 | ||||||
2023-11-16 | VNRX | Volitionrx Ltd | Butera Salvatore Thomas | CEO - Volition Veterinary | P - Purchase | $0.81 | +10,000 | 258,223 | +4% | +$8,100 | ||||||
2023-11-13 | LNTH | Lantheus Holdings, Inc. | Heino Mary Anne | CEO | S - Sale | $63.72 | -11,780 | 696,667 | -2% | -$750,611 | ||||||
2023-11-13 | LNTH | Lantheus Holdings, Inc. | Sabens Andrea | Chief Accounting Officer | S - Sale | $63.57 | -341 | 59,426 | -1% | -$21,677 | ||||||
2023-11-01 | MYGN | Myriad Genetics Inc | Riggsbee Richard Bryan | CFO | S - Sale | $15.69 | -30,000 | 321,812 | -9% | -$470,622 | ||||||
2023-11-03 | NEOG | Neogen Corp | Boehm William T | Dir | P - Purchase | $16.06 | +2,000 | 26,509 | +8% | +$32,110 | ||||||
2023-10-31 | NTLA | Intellia Therapeutics, Inc. | Bhanji Muna | Dir | S - Sale | $23.90 | -265 | 11,996 | -2% | -$6,334 | ||||||
2023-10-25 | NEOG | Neogen Corp | Jones Douglas Edward | COO | P - Purchase | $15.17 | +10,000 | 36,131 | +38% | +$151,727 | ||||||
2023-10-13 | NEOG | Neogen Corp | Lilly Jason Warren | VP | S - Sale | $15.10 | -351 | 26,744 | -1% | -$5,300 | ||||||
2023-06-02 | LNTH | Lantheus Holdings, Inc. | Baylor-Henry Minnie | Dir | S - Sale | $86.22 | -6 | 16 | -27% | -$517 | ||||||
2023-10-12 | NEOG | Neogen Corp | Tobin James P | Dir | P - Purchase | $15.19 | +3,000 | 20,392 | +17% | +$45,567 | ||||||
2023-10-11 | NEOG | Neogen Corp | Boehm William T | Dir | S - Sale | $15.61 | -2,591 | 24,509 | -10% | -$40,456 | ||||||
2023-10-11 | NEOG | Neogen Corp | Lilly Jason Warren | VP | S - Sale | $15.69 | -1,917 | 25,944 | -7% | -$30,087 | ||||||
2023-10-11 | NEOG | Neogen Corp | Naemura David H. | CFO | P - Purchase | $15.03 | +10,000 | 10,000 | New | +$150,333 | ||||||
2023-09-19 | TKNO | Alpha Teknova, Inc. | Telegraph Hill Partners Iv, L.P. | 10% | P - Purchase | $1.85 | +8,108,107 | 25,620,792 | +46% | +$14,999,998 | ||||||
2023-09-19 | TKNO | Alpha Teknova, Inc. | Terrill Damon | GC, CCO | P - Purchase | $1.85 | +27,027 | 41,027 | +193% | +$50,000 | ||||||
2023-09-19 | TKNO | Alpha Teknova, Inc. | Mackowski J Matthew | Dir | P - Purchase | $1.85 | +810,810 | 820,810 | >999% | +$1,499,999 | ||||||
2023-09-19 | TKNO | Alpha Teknova, Inc. | Lowell Matthew | CFO | P - Purchase | $1.85 | +54,054 | 88,054 | +159% | +$100,000 | ||||||
2023-09-19 | TKNO | Alpha Teknova, Inc. | Gunstream Stephen | Pres, CEO | P - Purchase | $1.85 | +54,054 | 162,852 | +50% | +$100,000 | ||||||
| D | 2023-09-15 | LNTH | Lantheus Holdings, Inc. | Niedzwiecki Daniel | See Remarks | S - Sale+OE | $66.43 | -2,846 | 66,295 | -4% | -$189,060 | |||||
2023-08-31 | VNRX | Volitionrx Ltd | Henshall Mickie | Dir | P - Purchase | $1.25 | +3,706 | 18,706 | +25% | +$4,633 | ||||||
2023-09-08 | AWH | Aspira Women'S Health Inc. | Hombeck Torsten | CFO | P - Purchase | $4.30 | +2,246 | 3,000 | +298% | +$9,658 | ||||||
| M | 2023-08-25 | CDIO | Cardio Diagnostics Holdings, Inc. | Dogan Meeshanthini | CEO, 10% | P - Purchase | $0.55 | +18,251 | 128,345 | +17% | +$9,964 | |||||
| M | 2023-08-25 | CDIO | Cardio Diagnostics Holdings, Inc. | Dogan Timur | CTO | P - Purchase | $0.55 | +18,251 | 128,345 | +17% | +$9,964 | |||||
2023-09-05 | VNRX | Volitionrx Ltd | Barnes Phillip | Dir | P - Purchase | $1.30 | +5,000 | 24,686 | +25% | +$6,500 | ||||||
| D | 2023-08-31 | IDXX | Idexx Laboratories Inc /de | Mazelsky Jonathan Jay | Pres, CEO | S - Sale+OE | $512.01 | -13,424 | 72,925 | -16% | -$6,873,267 | |||||
| M | 2023-08-24 | CDIO | Cardio Diagnostics Holdings, Inc. | Philibert Robert | Chief Medical Officer, 10% | P - Purchase | $0.60 | +34,000 | 3,281,584 | +1% | +$20,395 | |||||
2023-08-31 | VNRX | Volitionrx Ltd | Faulkes Martin Charles | Dir | P - Purchase | $1.28 | +9,716 | 2,029,532 | 0% | +$12,436 | ||||||
| D | 2023-08-29 | IDXX | Idexx Laboratories Inc /de | Polewaczyk James F | EVP | S - Sale+OE | $510.56 | -22,909 | 10,038 | -70% | -$11,696,446 | |||||
| M | 2023-08-29 | VNRX | Volitionrx Ltd | Micallef Jacob Vincent | Chief Scientific Officer | P - Purchase | $1.25 | +20,000 | 328,253 | +6% | +$25,063 | |||||
2023-08-25 | VNRX | Volitionrx Ltd | Micallef Jacob Vincent | Chief Scientific Officer | P - Purchase | $1.24 | +20,000 | 308,253 | +7% | +$24,800 | ||||||
2023-08-24 | VNRX | Volitionrx Ltd | Kway Jasmine | CEO - Singapore Volition | P - Purchase | $1.20 | +5,000 | 86,840 | +6% | +$6,000 | ||||||
2023-08-24 | VNRX | Volitionrx Ltd | Futcher Edward | Dir | P - Purchase | $1.22 | +5,000 | 418,936 | +1% | +$6,100 | ||||||
2023-08-24 | MYMD | Mymd Pharmaceuticals, Inc. | Rivard Paul | GC | P - Purchase | $1.11 | +150,000 | 400,000 | +60% | +$166,500 | ||||||
2023-08-24 | VNRX | Volitionrx Ltd | Michel Gaetan | COO | P - Purchase | $1.23 | +5,000 | 212,997 | +2% | +$6,150 | ||||||
2023-08-21 | LNTH | Lantheus Holdings, Inc. | Blanchfield Paul | Pres | S - Sale | $66.10 | -408 | 90,067 | 0% | -$26,969 | ||||||
2023-08-18 | LNTH | Lantheus Holdings, Inc. | Blanchfield Paul | Pres | S - Sale | $65.19 | -1,500 | 90,475 | -2% | -$97,785 | ||||||
| D | 2023-08-18 | NEOG | Neogen Corp | Boehm William T | Dir | S - Sale+OE | $22.59 | -1,500 | 24,509 | -6% | -$33,891 | |||||
2023-08-17 | MYMD | Mymd Pharmaceuticals, Inc. | Rivard Paul | GC | P - Purchase | $1.12 | +25,000 | 250,000 | +11% | +$28,080 | ||||||
2023-08-15 | IDXX | Idexx Laboratories Inc /de | Ayers Jonathan W | Dir | S - Sale | $0.00 | -492 | 595,547 | 0% | -$0 | ||||||
2023-08-15 | LNTH | Lantheus Holdings, Inc. | Marshall Robert J. Jr. | CFO, Treasurer | S - Sale | $68.52 | -10,000 | 108,298 | -8% | -$685,200 | ||||||
2023-08-16 | VNRX | Volitionrx Ltd | Butera Salvatore Thomas | CEO - Volition Veterinary | P - Purchase | $1.21 | +8,000 | 254,057 | +3% | +$9,680 | ||||||
2023-08-16 | VNRX | Volitionrx Ltd | Reynolds Cameron John | Pres, CEO | P - Purchase | $1.22 | +10,000 | 2,536,312 | 0% | +$12,200 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |